NCT00679042 · ClinicalTrials.gov record · last posted 2026-04-06
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
StatusActive, Not Recruiting
PhasePhase 3
Started2007-09-05
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation, and medical treatment at UIC. Therefore, the primary purpose of the present Phase 3 clinical trial is to demonstrate the safety and efficacy of allogeneic islet transplantation in improving glycemic control in Type 1 diabetic patients using the UIC protocol that was developed and proven effective during the Phase 1/2 clinical trial.
Amendment record
19 amendments on the ClinicalTrials.gov record
This ClinicalTrials.gov record has been amended 19 times since 2008-05-15; most recent amendment 2026-03-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history.
See every version on ClinicalTrials.gov ↗
2019-01-22
Status change Recruiting→Active, Not Recruitingv12
2019-01-06
Status change Active, Not Recruiting→Recruitingv11
2018-07-12
Status change Completed→Active, Not Recruitingv10
2018-05-17
Status change Recruiting→Completedv9
| NCT Number |
NCT00679042 |
| Lead Sponsor |
CellTrans Inc.
|
| Conditions |
Type 1 Diabetes Mellitus |
| Enrollment |
21 participants |
| Start Date |
2007-09-05 |
| Primary Completion |
2017-07-19 (estimated) |
| Study Completion |
2026-06-14 (estimated) |
| Updated on ClinicalTrials.gov |
2026-04-06 |